Abstract

Tuberculosis (TB) is a globally prevalent disease that is caused by the aerobic, grampositive agent Mycobacterium tuberculosis. Despite the accessibility of broad-spectrum
antibiotics which are very effective against M. tuberculosis, the social and financial burden of the patients with the disease continues to be huge, especially in the developing regions such as India and sub-Saharan Africa. This is mainly owing to limited laboratory infrastructure, treatment with the least sensitive diagnostics, and non-adherence to the
standard therapeutic regimens.